Welcome to our dedicated page for Dyadic Intl Del news (Ticker: DYAI), a resource for investors and traders seeking the latest updates and insights on Dyadic Intl Del stock.
Dyadic International, Inc. (Nasdaq: DYAI), doing business as Dyadic Applied BioSolutions, regularly issues news on its activities as a global biotechnology company producing precision-engineered, animal-free proteins and enzymes. This news page aggregates press releases and market updates that describe how Dyadic is advancing its microbial C1 and Dapibus™ expression platforms across life sciences, food and nutrition, and bio-industrial markets.
Readers can find announcements about commercial agreements and partnerships, such as collaborations with Proliant Health and Biologicals, Inzymes ApS, Fermbox Bio, BRIG BIO, and Opes Diagnostics. These items often cover milestones in recombinant serum albumin, transferrin, growth factors, non-animal dairy proteins, and industrial enzyme products like EN3ZYME™, as well as details on licensing structures, milestone payments, and revenue-sharing arrangements.
Dyadic’s news flow also includes financial results and corporate developments, including quarterly earnings releases, equity offerings, and updates on its strategic shift from a research-driven organization to a commercially focused biotechnology company. These releases highlight progress in expanding product pipelines, scaling manufacturing, and strengthening liquidity to support commercial growth.
Another recurring theme in DYAI news is technology and platform validation. Articles describe grant-funded programs with organizations such as the Bill & Melinda Gates Foundation and CEPI, peer-reviewed publications demonstrating the capabilities of the C1 platform for vaccine antigens, and the CRISPR/Cas9 license agreement with ERS Genomics that broadens Dyadic’s genetic engineering toolkit.
Investors, analysts, and industry participants can use this page to follow Dyadic’s evolving portfolio of recombinant proteins, its regional expansion efforts, and its responses to Nasdaq listing matters disclosed in SEC filings. Bookmark this section to review the company’s historical and ongoing news as it reports commercial milestones, scientific progress, and capital markets activity.
Dyadic International (NASDAQ:DYAI), a global biotechnology company, has announced the pricing of its underwritten public offering of 6,052,000 shares of common stock. The offering is expected to close on August 1, 2025, with Craig-Hallum Capital Group LLC serving as the sole managing underwriter.
The company plans to use the net proceeds for working capital and general corporate purposes, including product development, sales, and marketing. The offering is being made pursuant to an effective shelf registration statement on Form S-3 filed with the SEC.
Dyadic International (NASDAQ:DYAI), a global biotechnology company specializing in precision engineered functional input proteins, has announced a proposed underwritten public offering of common stock. The offering will be managed by Craig-Hallum Capital Group LLC as the sole underwriter.
The company plans to use the proceeds for working capital and general corporate purposes, including product development, sales, and marketing. The offering is being made pursuant to an effective shelf registration statement on Form S-3 filed with the SEC. The final terms of the offering will be disclosed in a final prospectus supplement.
Dyadic International (NASDAQ:DYAI) announced its strategic rebranding to Dyadic Applied BioSolutions, effective in 30 days, marking its transition from research to commercial focus. The company, leveraging its proprietary C1 and Dapibus™ gene expression platforms, aims to commercialize non-therapeutic proteins for life sciences, food, nutrition, and industrial biotechnology applications.
Recent achievements include a $250,000 milestone payment from a non-animal dairy enzyme program and securing a $1.5 million second installment from a $3.0 million Gates Foundation grant for developing low-cost monoclonal antibodies. The company is on track to commercialize its input proteins in 2025.
Dyadic International (NASDAQ: DYAI), a biotechnology company specializing in large-scale protein manufacturing for vaccines, therapeutics, and industrial applications, has scheduled its Q1 2025 financial results announcement and corporate update conference call for Wednesday, May 14, 2025, at 5:00 PM ET.
Shareholders and interested parties can access the call through toll-free (+1-877-407-0784) or international (+1-201-689-8560) numbers using Conference ID 13751387. A webcast will be available, with an archive accessible within 24 hours on Dyadic's Investor Relations website.
Dyadic International (Nasdaq: DYAI) has announced its participation in the 2025 World Vaccine Congress in Washington, D.C. CEO Mark Emalfarb will present on April 23, 2025, focusing on the company's C1 Platform and its application in addressing avian influenza (H5N1) and future pandemics.
The presentation, scheduled for 12:40 PM-1:10 PM in Room 202A, will showcase recent preclinical research utilizing Dyadic's proprietary C1 expression platform. The company will highlight data related to the production of non-mRNA antigens and reagents for vaccine production, demonstrating the platform's ability to elicit high neutralizing antibodies.
The C1 platform aims to enable rapid, cost-effective production of antigens, reagents, and cell culture media products to address global health challenges through scalable biomanufacturing. Interested parties can meet the management team at booth #654 or schedule meetings via assistant@dyadic.com.
Dyadic International (NASDAQ: DYAI) reported its 2024 financial results, highlighting significant progress in commercializing its Dapibus™ and C1 microbial protein production platforms. The company achieved $1.9 million in milestone and license revenue and secured up to $7.5 million in grants from CEPI and Gates Foundation.
Key financial metrics include:
- Total revenue increased to $3.5 million (vs $2.9 million in 2023)
- Net loss decreased to $5.8 million or $(0.20) per share (vs $6.8 million in 2023)
- Cash position of $9.3 million as of December 31, 2024
Notable developments include advancing Human Serum Albumin toward commercial launch in Q2 2025, expanding alternative protein portfolio with six life science products, and progressing in animal and human health applications. The company is developing multiple products nearing market launch, including DNASe1 and various enzymes for non-animal dairy applications.
Dyadic International (NASDAQ: DYAI) has received a $4.5 million funding award from CEPI to accelerate protein-based vaccine development using their C1 filamentous fungus technology. The funding will be directed to Fondazione Biotecnopolo di Siena (FBS) for proof-of-concept research.
The project aims to demonstrate that C1 technology could reduce vaccine production time from the current 4-6 months to just 35 days, significantly accelerating Phase 1 trials. Unlike traditional mammalian cell production, C1 fungus can rapidly produce quality vaccine proteins without extensive testing requirements.
The research will compare SARS-CoV-2 spike protein production using both C1 fungus and mammalian cell approaches. If successful, the technology could enable faster, more cost-effective vaccine manufacturing, particularly beneficial for regions with less established infrastructure, supporting the G7 and G20's 100 Days Mission for pandemic response.
Dyadic International (Nasdaq: DYAI), a biotechnology company specializing in large-scale protein manufacturing for human and animal vaccines, therapeutics, and non-pharmaceutical applications, has announced its upcoming 2024 full-year financial results release and conference call.
The company will host the corporate update conference call on Wednesday, March 26, 2025, at 5:00 p.m. Eastern Time. Investors can access the call through toll-free (+1-877-407-0784) or international (+1-201-689-8560) numbers using Conference ID 13751386. A webcast will also be available, with an archive accessible within 24 hours on Dyadic's Investor Relations website.
FAQ
What is the current stock price of Dyadic Intl Del (DYAI)?
What is the market cap of Dyadic Intl Del (DYAI)?
